|Articles|August 15, 2002
- BioPharm International-08-01-2002
- Volume 15
- Issue 8
Inside Washington: User Fee Program Seeks to Spur Biotech Development
Author(s)Jill Wechsler
PDUFA III boost manufacturer fees to cover postapproval surveillance and streamline the FDA review process
Advertisement
Articles in this issue
about 23 years ago
Guest Editorial: Quality Agreements with Contract Laboratoriesabout 23 years ago
Analytical Advances: Mapping Proteins – the 2-D Electrophoresis Issueabout 23 years ago
Your Vested Interests: Gorillas In Our MidstNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
